
Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence - European Journal of Medical Research
Obesity, clinically defined by pathological adipose tissue accumulation disrupting metabolic homeostasis, has reached pandemic proportions. The World Obesity Atlas 2024 reports over 1.5 billion projected cases by 2035, highlighting its growing threat among pediatric and adult populations...

Quoting from the summary on Suppversity -
"How does it work? The anti-obesity efficacy work their magic via five core pathways:
(1) Transcriptional Regulation: Suppression of adipocyte differentiation genes and modulation of metabolic adipokine networks.
(2) Thermogenic Activation: Promotion of BAT activity and WAT browning via mitochondrial uncoupling mechanisms.
(3) Lipid Homeostasis: Modulation of plaque metabolism through LOX-1 downregulation and LDLR/SREBP2/CYP7A1 axis activation.
(4) Gut-Microbiota Crosstalk: Remodeling of enteric microbial composition and reinforcement of intestinal barrier integrity.
(5) Immunometabolic Reprogramming: Polarization of ATMs toward M2 phenotypes with concurrent suppression of NF-κB/STAT3 inflammatory cascades."